key: cord-1022675-5l0cqmw6
authors: Langerbeins, Petra; Fürstenau, Moritz; Gruell, Henning; Klein, Florian; Persigehl, Thorsten; Rybniker, Jan; Seeger‐Nukpezah, Tamina; Kochanek, Matthias; Hallek, Michael; Eichhorst, Barbara; Koehler, Philipp; Böll, Boris
title: COVID‐19 complicated by parainfluenza co‐infection in a patient with chronic lymphocytic leukemia
date: 2020-07-10
journal: Eur J Haematol
DOI: 10.1111/ejh.13475
sha: 1e9399a0a4991bbb45e149705fee80f8367e4cfb
doc_id: 1022675
cord_uid: 5l0cqmw6

The number of people suffering from the new coronavirus SARS‐CoV‐2 continues to rise. In SARS‐CoV‐2, superinfection with bacteria or fungi seems to be associated with increased mortality. The role of co‐infections with respiratory viral pathogens has not yet been clarified. Here, we report the course of COVID‐19 in a CLL patient with secondary immunodeficiency and viral co‐infection with parainfluenza.

At the time of positive SARS-CoV-2 PCR, he presented himself in the emergency room with a productive cough (brownish, mucous secretion) that had been present for 5 days, ageusia and hyposmia.

At Day 0, conspicuous laboratory values were a C-reactive protein of 27.2 mg/L, leukocytes of 28.6 × 10 9 /L, and platelets of 114 × 10 9 /L. Due to his good general condition and only mild symptoms present, the patient was put under home quarantine with regular follow-up telephone visits scheduled. On Day 7, the patient was admitted to the hospital due to deteriorating general state of health with increasing respiratory distress. Laboratory values at admission were a C-reactive protein of 25.6 mg/L, procalcitonin of 0.5 µg/L, leukocytes 18.4 × 10 9 /L, and platelets of 115 × 10 9 /L. As COVID-19 proceeded, we observed a further drop in leukocytes and neutropenia advanced from Common Terminology Criteria for Adverse Events 

We report the interdisciplinary treatment of a CLL patient with 

All authors contributed toward patient care, collection and assembly of data, data analysis and interpretation, manuscript writing, and final manuscript approval.

The patient was enrolled in the protocol Improving Diagnosis of Severe Infections of Immunocompromised Patients (ISI, Identifier of the University of Cologne Ethics Committee 08-160) and signed informed consent.

https://orcid.org/0000-0002-6654-0304

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

Perturbation of the normal immune system in patients with CLL

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

IgA levels at diagnosis predict for infections, time to treatment, and survival in chronic lymphocytic leukemia

The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation